董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ron Mayron | 男 | Director | 59 | 27.90万美元 | 未持股 | 2023-08-15 |
| Gerald Lieberman | 男 | Director, Chairman of the Board | 76 | 25.70万美元 | 未持股 | 2023-08-15 |
| Yonatan Malca | 男 | Director | 57 | 25.20万美元 | 未持股 | 2023-08-15 |
| Miranda J. Toledano | 女 | Chief Executive Officer and Director | 46 | 67.90万美元 | 未持股 | 2023-08-15 |
| Sean Ellis | 男 | Director | 48 | 24.80万美元 | 未持股 | 2023-08-15 |
| Ron Mayron | 男 | Director | 60 | 未披露 | 未持股 | 2023-08-15 |
| Haya Taitel | 女 | Director | 60 | 未披露 | 未持股 | 2023-08-15 |
| Roger J. Garceau | 男 | Director | 69 | 23.70万美元 | 未持股 | 2023-08-15 |
| Gerald M. Ostrov | 男 | Director | 73 | 25.20万美元 | 未持股 | 2023-08-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Hillel Galitzer | 男 | Chief Operating Officer | 45 | 62.10万美元 | 未持股 | 2023-08-15 |
| Dana Yaacov Garbeli | 女 | Chief Financial Officer | 39 | 未披露 | 未持股 | 2023-08-15 |
| Arthur Santora | 男 | Chief Medical Officer | 72 | 未披露 | 未持股 | 2023-08-15 |
| Miranda J. Toledano | 女 | Chief Executive Officer and Director | 46 | 67.90万美元 | 未持股 | 2023-08-15 |
董事简历
中英对照 | 中文 | 英文- Ron Mayron
-
Ron Mayron，他也曾任职Icecure Medical Ltd.的董事会，担任独立董事（2011年4月以来），也是Icecure Medical Ltd.的审计、薪酬、财务报表、公司治理和投资委员会的成员。他担任ADY Consulting Group的战略和业务顾问。任职ADY Consulting Group之前，他曾担任Netafim公司的联席首席执行官。此前，他曾担任Teva公司的多种高级职务20年以上，包括高级商业开发副总裁、首席信息官、中欧和东欧副总裁。他持有Bar Ilan University的经济学学士学位。
Ron Mayron has served as Chairman of Icecure Medical Ltd. board of directors since December 2017. Mr. Mayron has served as chairman of the board of directors of Resymmetry Ltd. since July 2016 InnoCan Pharma Corporation CSE: INNO, FWB: IP4 OTC: INNPF since November 2017 and Virility Medical LTD since October 2019 and as a member of the board of directors of BioLight Life Sciences Investments Ltd. (TASE: BOLT) since August 2015 G-Med Ltd. since September 2015 Kaizen Bio-Tec Ltd. since May 2017 Simplivia Ltd. since May 2019 and Kadimastem LTD (TASE: KDST) since December 2020. Mr. Mayron has also served as the founder and chief executive officer of RonMed Ltd. Prior to that, Mr. Mayron has served as chairman of the board of directors of Wize Pharma Inc. (OTC: WIZP) from April 2015 to October 2018 and Ocon Medical Ltd from January 2015 to November 2016 and as a member of the board of directors of EclipeIR (USA) Inc from June 2016 to September 2019. Mr. Mayron has also served in various positions at Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) from 1993 to 2014 including as vice president -Israel and Africa and chief executive officer of Teva Israel from 2009 to 2013. Mr. Mayron received his B.Sc. in industrial and management engineering from Ben-Gurion University of the Negev, Israel and MBA from Tel-Aviv University, Israel. Mr. Mayron also completed a special senior management and global leadership programs at the Massachusetts Institute of Technology (M.I.T), Boston and managerial skills for international business and executive international marketing programs at Insead University, France. - Ron Mayron，他也曾任职Icecure Medical Ltd.的董事会，担任独立董事（2011年4月以来），也是Icecure Medical Ltd.的审计、薪酬、财务报表、公司治理和投资委员会的成员。他担任ADY Consulting Group的战略和业务顾问。任职ADY Consulting Group之前，他曾担任Netafim公司的联席首席执行官。此前，他曾担任Teva公司的多种高级职务20年以上，包括高级商业开发副总裁、首席信息官、中欧和东欧副总裁。他持有Bar Ilan University的经济学学士学位。
- Ron Mayron has served as Chairman of Icecure Medical Ltd. board of directors since December 2017. Mr. Mayron has served as chairman of the board of directors of Resymmetry Ltd. since July 2016 InnoCan Pharma Corporation CSE: INNO, FWB: IP4 OTC: INNPF since November 2017 and Virility Medical LTD since October 2019 and as a member of the board of directors of BioLight Life Sciences Investments Ltd. (TASE: BOLT) since August 2015 G-Med Ltd. since September 2015 Kaizen Bio-Tec Ltd. since May 2017 Simplivia Ltd. since May 2019 and Kadimastem LTD (TASE: KDST) since December 2020. Mr. Mayron has also served as the founder and chief executive officer of RonMed Ltd. Prior to that, Mr. Mayron has served as chairman of the board of directors of Wize Pharma Inc. (OTC: WIZP) from April 2015 to October 2018 and Ocon Medical Ltd from January 2015 to November 2016 and as a member of the board of directors of EclipeIR (USA) Inc from June 2016 to September 2019. Mr. Mayron has also served in various positions at Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) from 1993 to 2014 including as vice president -Israel and Africa and chief executive officer of Teva Israel from 2009 to 2013. Mr. Mayron received his B.Sc. in industrial and management engineering from Ben-Gurion University of the Negev, Israel and MBA from Tel-Aviv University, Israel. Mr. Mayron also completed a special senior management and global leadership programs at the Massachusetts Institute of Technology (M.I.T), Boston and managerial skills for international business and executive international marketing programs at Insead University, France.
- Gerald Lieberman
-
Gerald Lieberman Lieberman先生自2014年4月起担任我们的董事会成员，并于2019年7月成为我们的董事长。Lieberman先生还是Teva Pharmaceutical Industries Ltd.的董事会成员。他曾担任NYSE and TASE:Teva公司（全球领先的制药公司，也是世界上最大的仿制药开发商和制造商）的审计委员会主席，也任职于人力资源和薪酬委员会、财务委员会。他还担任DosenRx，Ltd.的董事会主席，该公司是一家数字健康公司，开发了个性化、病人控制的交付药物的设备。他目前也是Reverence Capital Partners公司（私人投资公司，专注于中间市场金融服务行业）的特别顾问。Lieberman从2000年到2009年担任Alliance Bernstein L.P.高管，2004年到2009年担任总裁和首席运营官，2003年到2004年担任首席运营官，2000年到2003年担任Vice President、财务和运营主管。从1998年到2000年，他担任Sanford C.Bernstein&Co.，Inc.的财务和行政高级副总裁，，直到2000年该公司被Alliance Capital收购，成立AllianceBernstein L.P.。加入Citicorp公司之前，他曾担任Arthur Andersen公司的注册会计师。他此前曾任职Forest Laboratories公司（从2011年到2014年）、Computershare公司（从2010年到2012年）、AllianceBernstein L.P.（从2004年到2009年）的董事会。Lieberman先生在康涅狄格大学（University of Connecticut）以优异的商业成绩获得了B.S.Beta Gamma Sigma。
Gerald Lieberman,has served as a member of Entera Bio Ltd. Board since April 2014 and became Entera Bio Ltd. Chairman in July 2019. Mr. Lieberman is also a member of the board of directors of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global leader in pharmaceuticals and the world's largest generic drug developer and manufacturer, where he chairs the Audit Committee and serves on both the Human Resources and Compensation Committee and the Finance Committee. He also serves as Chairman of the Board of Directors of DosenRx, Ltd., a Digital health company that has developed a personalized, patient-controlled device for delivering medication. He is also currently a special advisor at Reverence Capital Partners, a private investment firm focused on the middle-market financial services industry. From 2000 to 2009, Mr. Lieberman was an executive at Alliance Bernstein L.P., where he served as President and Chief Operating Officer from 2004 to 2009, as Chief Operating Officer from 2003 to 2004 and as Executive Vice President, Finance and Operations from 2000 to 2003. From 1998 to 2000, he served as Senior Vice President, Finance and Administration at Sanford C. Bernstein & Co., Inc., until it was acquired by Alliance Capital in 2000, forming Alliance Bernstein L.P. Prior to that, he served in various executive positions at Fidelity Investments and at Citicorp. Prior to joining Citicorp he was a certified public accountant with Arthur Andersen. He previously served on the board of directors of Forest Laboratories, LLC from 2011 to 2014, Computershare Ltd. from 2010 to 2012 and Alliance Bernstein L.P. from 2004 to 2009. Mr. Lieberman received a B.S. Beta Gamma Sigma with honors in business from the University of Connecticut. - Gerald Lieberman Lieberman先生自2014年4月起担任我们的董事会成员，并于2019年7月成为我们的董事长。Lieberman先生还是Teva Pharmaceutical Industries Ltd.的董事会成员。他曾担任NYSE and TASE:Teva公司（全球领先的制药公司，也是世界上最大的仿制药开发商和制造商）的审计委员会主席，也任职于人力资源和薪酬委员会、财务委员会。他还担任DosenRx，Ltd.的董事会主席，该公司是一家数字健康公司，开发了个性化、病人控制的交付药物的设备。他目前也是Reverence Capital Partners公司（私人投资公司，专注于中间市场金融服务行业）的特别顾问。Lieberman从2000年到2009年担任Alliance Bernstein L.P.高管，2004年到2009年担任总裁和首席运营官，2003年到2004年担任首席运营官，2000年到2003年担任Vice President、财务和运营主管。从1998年到2000年，他担任Sanford C.Bernstein&Co.，Inc.的财务和行政高级副总裁，，直到2000年该公司被Alliance Capital收购，成立AllianceBernstein L.P.。加入Citicorp公司之前，他曾担任Arthur Andersen公司的注册会计师。他此前曾任职Forest Laboratories公司（从2011年到2014年）、Computershare公司（从2010年到2012年）、AllianceBernstein L.P.（从2004年到2009年）的董事会。Lieberman先生在康涅狄格大学（University of Connecticut）以优异的商业成绩获得了B.S.Beta Gamma Sigma。
- Gerald Lieberman,has served as a member of Entera Bio Ltd. Board since April 2014 and became Entera Bio Ltd. Chairman in July 2019. Mr. Lieberman is also a member of the board of directors of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global leader in pharmaceuticals and the world's largest generic drug developer and manufacturer, where he chairs the Audit Committee and serves on both the Human Resources and Compensation Committee and the Finance Committee. He also serves as Chairman of the Board of Directors of DosenRx, Ltd., a Digital health company that has developed a personalized, patient-controlled device for delivering medication. He is also currently a special advisor at Reverence Capital Partners, a private investment firm focused on the middle-market financial services industry. From 2000 to 2009, Mr. Lieberman was an executive at Alliance Bernstein L.P., where he served as President and Chief Operating Officer from 2004 to 2009, as Chief Operating Officer from 2003 to 2004 and as Executive Vice President, Finance and Operations from 2000 to 2003. From 1998 to 2000, he served as Senior Vice President, Finance and Administration at Sanford C. Bernstein & Co., Inc., until it was acquired by Alliance Capital in 2000, forming Alliance Bernstein L.P. Prior to that, he served in various executive positions at Fidelity Investments and at Citicorp. Prior to joining Citicorp he was a certified public accountant with Arthur Andersen. He previously served on the board of directors of Forest Laboratories, LLC from 2011 to 2014, Computershare Ltd. from 2010 to 2012 and Alliance Bernstein L.P. from 2004 to 2009. Mr. Lieberman received a B.S. Beta Gamma Sigma with honors in business from the University of Connecticut.
- Yonatan Malca
-
Yonatan Malca自2011年以来一直担任我们的董事会成员。他目前担任D.N.A Biomedical公司的首席执行官兼董事（2010年以来）。Malca先生还担任Arko Holdings Ltd.的董事。TASE:Arko，NextGen-BioMed Ltd.TASE:NXGN和Tamda Ltd.（TASE:TMDA），均为以色列上市公司。Malca先生还任职于多家私人公司的董事会，包括担任医疗器械公司CardioArt Technologies Ltd.和医疗器械公司Beamed Ltd.（D.N.A Biomedical的子公司）的董事会主席。Malca先生拥有以色列巴伊兰大学（Bar-Ilan University）的经济学和统计学学士学位以及巴伊兰大学（Bar Ilan University）的经济学和金融学硕士学位。
Yonatan Malca,has served as a member of Entera Bio Ltd. Board since 2011. Mr. Malca currently serves as a Chief Executive Officer and director of NanoGohst Ltd. Since 2010 until 2021, he served as a Chief Executive Officer and director of D.N.A Biomedical Mr. Malca also serves as a director of Nextgen-Biomed LTD. (TASE: NXGN) and Jungo Connectivity Ltd. (TASE: JNGO), each of which is an Israeli public company. Mr. Malca holds a B.A. in Economics and Statistics from Bar-Ilan University and an M.A. in Economics and Finance from Bar Ilan University, Israel. - Yonatan Malca自2011年以来一直担任我们的董事会成员。他目前担任D.N.A Biomedical公司的首席执行官兼董事（2010年以来）。Malca先生还担任Arko Holdings Ltd.的董事。TASE:Arko，NextGen-BioMed Ltd.TASE:NXGN和Tamda Ltd.（TASE:TMDA），均为以色列上市公司。Malca先生还任职于多家私人公司的董事会，包括担任医疗器械公司CardioArt Technologies Ltd.和医疗器械公司Beamed Ltd.（D.N.A Biomedical的子公司）的董事会主席。Malca先生拥有以色列巴伊兰大学（Bar-Ilan University）的经济学和统计学学士学位以及巴伊兰大学（Bar Ilan University）的经济学和金融学硕士学位。
- Yonatan Malca,has served as a member of Entera Bio Ltd. Board since 2011. Mr. Malca currently serves as a Chief Executive Officer and director of NanoGohst Ltd. Since 2010 until 2021, he served as a Chief Executive Officer and director of D.N.A Biomedical Mr. Malca also serves as a director of Nextgen-Biomed LTD. (TASE: NXGN) and Jungo Connectivity Ltd. (TASE: JNGO), each of which is an Israeli public company. Mr. Malca holds a B.A. in Economics and Statistics from Bar-Ilan University and an M.A. in Economics and Finance from Bar Ilan University, Israel.
- Miranda J. Toledano
-
MirandaJ.Toledano自2018年9月以来一直担任我们的董事会成员。Toledano女士担任Trigr Therapeutics（一家临床阶段免疫肿瘤公司，专注于双特异性抗体）的首席运营官/首席财务官。此前，从2016年9月至2017年8月，Toledano女士担任Sorrento Therapeutics NASDAQ:SRNE的执行管理团队执行副总裁。从2012年到2016年，Toledano女士担任MLV&Co.（被B.Riley FBR&Co.收购）的梦百合投资银行业务主管，在那里她完成了总价值超过40亿美元的股票资本市场交易。加入MLV之前，从2004年到2010年，Toledano女士在Royalty Pharma的投资集团任职，该公司是一家领先的投资公司，拥有超过150亿美元的生物治疗特许权使用费资产。从1998年到2003年，Toledano女士领导安永会计师事务所（Ernst&Young）（以色列）的生命科学公司财务集团。Toledano女士拥有塔夫茨大学（Tufts University）经济学学士学位和纽约大学斯特恩商学院（NYU Stern School of Business）金融与创业工商管理硕士学位。
Miranda J. Toledano,has served as the Company's Chief Executive Officer, or CEO, since July 2022. Prior to her appointment as CEO, Ms. Toledano served as the Company's Chief Business Officer, Chief Financial Officer and Head of Corporate Strategy since May 2022. Ms. Toledano has over 20 years of C-level leadership, principal investment and Wall Street/capital market experience in the biotech sector. Ms. Toledano has served as a member of Entera Bio Ltd. Board of Directors (the "Board") since 2018, and as Member of the Scientific Advisory Committee since February 2022. Previously, Miranda served as Chief Operating Officer, Chief Financial Officer, and Director of TRIGR Therapeutics, an oncology focused, clinical stage bispecific antibody company, from August 2018 until its acquisition by Compass Therapeutics (Nasdaq: CMPX) in June 2021. At TRIGR, Miranda oversaw the clinical development of lead asset TR009 (now CTX-009) and led strategic execution, including a $117 million China License Transaction and acquisition by CMPX. Previously, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings (IPOs, ATMs, and follow-ons) totaling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma (Nasdaq: RPRX) from 2004 to 2010. Ms. Toledano is also a member of the board of directors of Journey Medical (Nasdaq: DERM) and NEXGEL (Nasdaq: NXGL). Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business. - MirandaJ.Toledano自2018年9月以来一直担任我们的董事会成员。Toledano女士担任Trigr Therapeutics（一家临床阶段免疫肿瘤公司，专注于双特异性抗体）的首席运营官/首席财务官。此前，从2016年9月至2017年8月，Toledano女士担任Sorrento Therapeutics NASDAQ:SRNE的执行管理团队执行副总裁。从2012年到2016年，Toledano女士担任MLV&Co.（被B.Riley FBR&Co.收购）的梦百合投资银行业务主管，在那里她完成了总价值超过40亿美元的股票资本市场交易。加入MLV之前，从2004年到2010年，Toledano女士在Royalty Pharma的投资集团任职，该公司是一家领先的投资公司，拥有超过150亿美元的生物治疗特许权使用费资产。从1998年到2003年，Toledano女士领导安永会计师事务所（Ernst&Young）（以色列）的生命科学公司财务集团。Toledano女士拥有塔夫茨大学（Tufts University）经济学学士学位和纽约大学斯特恩商学院（NYU Stern School of Business）金融与创业工商管理硕士学位。
- Miranda J. Toledano,has served as the Company's Chief Executive Officer, or CEO, since July 2022. Prior to her appointment as CEO, Ms. Toledano served as the Company's Chief Business Officer, Chief Financial Officer and Head of Corporate Strategy since May 2022. Ms. Toledano has over 20 years of C-level leadership, principal investment and Wall Street/capital market experience in the biotech sector. Ms. Toledano has served as a member of Entera Bio Ltd. Board of Directors (the "Board") since 2018, and as Member of the Scientific Advisory Committee since February 2022. Previously, Miranda served as Chief Operating Officer, Chief Financial Officer, and Director of TRIGR Therapeutics, an oncology focused, clinical stage bispecific antibody company, from August 2018 until its acquisition by Compass Therapeutics (Nasdaq: CMPX) in June 2021. At TRIGR, Miranda oversaw the clinical development of lead asset TR009 (now CTX-009) and led strategic execution, including a $117 million China License Transaction and acquisition by CMPX. Previously, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings (IPOs, ATMs, and follow-ons) totaling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma (Nasdaq: RPRX) from 2004 to 2010. Ms. Toledano is also a member of the board of directors of Journey Medical (Nasdaq: DERM) and NEXGEL (Nasdaq: NXGL). Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.
- Sean Ellis
-
Sean Ellis自2019年6月以来一直担任我们的董事会成员。Ellis先生是Centillion基金的基金经理，这是一家致力于以色列投资的风险资本基金，主要专注于生物技术和梦百合行业的投资。Centillion公司是Entera Bio公司最早的投资者和最大股东之一。Ellis先生也是Redstone Capital的管理合伙人和创始人，Redstone Capital是一家技术风险投资基金，在东欧运营，由SBI Japan等资助。他持有New York University的文学学士学位，以及Columbia University的工商管理硕士学位。
Sean Ellis,has served as a member of Entera Bio Ltd. Board since June 2019. Mr. Ellis is a fund manager of Centillion Fund, a venture capital fund dedicated to Israeli investments, with a primary focus on investments in the biotech and healthcare industries. Centillion is one of Entera Bio's earliest investors and largest shareholders. He holds a BA from New York University and MBA from Columbia University. - Sean Ellis自2019年6月以来一直担任我们的董事会成员。Ellis先生是Centillion基金的基金经理，这是一家致力于以色列投资的风险资本基金，主要专注于生物技术和梦百合行业的投资。Centillion公司是Entera Bio公司最早的投资者和最大股东之一。Ellis先生也是Redstone Capital的管理合伙人和创始人，Redstone Capital是一家技术风险投资基金，在东欧运营，由SBI Japan等资助。他持有New York University的文学学士学位，以及Columbia University的工商管理硕士学位。
- Sean Ellis,has served as a member of Entera Bio Ltd. Board since June 2019. Mr. Ellis is a fund manager of Centillion Fund, a venture capital fund dedicated to Israeli investments, with a primary focus on investments in the biotech and healthcare industries. Centillion is one of Entera Bio's earliest investors and largest shareholders. He holds a BA from New York University and MBA from Columbia University.
- Ron Mayron
-
Ron Mayron，自2021年4月起担任Entera Bio Ltd.董事会成员，是一名全球医疗保健专家，在以色列众多上市和私营制药和医疗设备公司的董事会任职，包括DNA BioMedical Solutions、Innocan Pharma和IceCure Medical。他之前的高管经历包括多个领导职位，2009年至2013年担任Teva Israel & Africa首席执行官，1999年至2007年担任S.L.E首席执行官。他在医疗保健领域的专长包括并购、整合和实施、全球业务发展、全球运营和供应链管理。他在本-古里安大学获得了理学学士学位，在特拉维夫大学获得了MBA学位，并在法国枫丹堡欧洲工商管理学院和波士顿麻省理工学院参加了多个项目。
Ron Mayron,has served as a member of Entera Bio Ltd. Board since April 2021 and is a global healthcare specialist who serves on the boards of numerous public and privately-held pharma and medical device companies in Israel, including DNA BioMedical Solutions, Innocan Pharma, and IceCure Medical. His prior executive experience includes several leadership positions culminating in CEO of Teva Israel & Africa from 2009 until 2013 and CEO of S.L.E from 1999 and until 2007. His expertise within healthcare includes M&A, integration and implementation, global business development, global operations, and supply chain management. He earned a B.Sc. from Ben-Gurion University, and an MBA from the University of Tel Aviv, and attended several programs at Insead University Fontainebleu, France and the Massachusetts Institute of Technology, Boston. - Ron Mayron，自2021年4月起担任Entera Bio Ltd.董事会成员，是一名全球医疗保健专家，在以色列众多上市和私营制药和医疗设备公司的董事会任职，包括DNA BioMedical Solutions、Innocan Pharma和IceCure Medical。他之前的高管经历包括多个领导职位，2009年至2013年担任Teva Israel & Africa首席执行官，1999年至2007年担任S.L.E首席执行官。他在医疗保健领域的专长包括并购、整合和实施、全球业务发展、全球运营和供应链管理。他在本-古里安大学获得了理学学士学位，在特拉维夫大学获得了MBA学位，并在法国枫丹堡欧洲工商管理学院和波士顿麻省理工学院参加了多个项目。
- Ron Mayron,has served as a member of Entera Bio Ltd. Board since April 2021 and is a global healthcare specialist who serves on the boards of numerous public and privately-held pharma and medical device companies in Israel, including DNA BioMedical Solutions, Innocan Pharma, and IceCure Medical. His prior executive experience includes several leadership positions culminating in CEO of Teva Israel & Africa from 2009 until 2013 and CEO of S.L.E from 1999 and until 2007. His expertise within healthcare includes M&A, integration and implementation, global business development, global operations, and supply chain management. He earned a B.Sc. from Ben-Gurion University, and an MBA from the University of Tel Aviv, and attended several programs at Insead University Fontainebleu, France and the Massachusetts Institute of Technology, Boston.
- Haya Taitel
-
Haya Taitel，拥有超过30年的全球C级生物制药商业和战略执行经验。Taitel女士目前担任赛诺菲全球移植特许经营权的负责人，负责提高特许经营权的增长和盈利能力。在加入赛诺菲之前，Taitel女士曾担任Kadmon Pharmaceuticals，LLC的首席商务官，从2013年开始，她为Rezurock 的推出做出了贡献，直到该公司于2021年11月被赛诺菲以19亿美元的价格收购。Taitel女士还领导了Kadmon Board的执行商务委员会。从1997年开始，Taitel女士在强生公司担任了多个商业领导职位，在多个治疗领域，包括肿瘤学、免疫学、神经学和妇女医疗保健领域，职位越来越高。Taitel女士拥有天普大学的理学硕士学位、药理学硕士学位（药学等效性）和以色列耶路撒冷希伯来大学药学院的理学学士学位、药学学士学位和生物学学士学位。
Haya Taitel,has over 30 years of global C-level biopharma commercial and strategic executive experience. Ms. Taitel currently serves as the Head of Sanofi's Global Transplant Franchise where she is responsible for increasing franchise growth and profitability. Prior to her role at Sanofi, Ms. Taitel served as the Chief Commercial Officer of Kadmon Pharmaceuticals, LLC, where she contributed to the launch of Rezurock, from 2013 until the company was acquired by Sanofi for $1.9 billion in November 2021. Ms. Taitel also led Kadmon Board's Executive Commercial Committee. Beginning in 1997, Ms. Taitel had held various commercial leadership positions of increasing seniority at Johnson and Johnson in multiple therapeutic areas, including oncology, immunology, neurology and women's healthcare. Ms. Taitel holds a Master of Science, Pharmacology, (PharmD equivalence) from Temple University and a Bachelor of Science, Pharmacy and Biology from the Hebrew University School of Pharmacy in Jerusalem, Israel. - Haya Taitel，拥有超过30年的全球C级生物制药商业和战略执行经验。Taitel女士目前担任赛诺菲全球移植特许经营权的负责人，负责提高特许经营权的增长和盈利能力。在加入赛诺菲之前，Taitel女士曾担任Kadmon Pharmaceuticals，LLC的首席商务官，从2013年开始，她为Rezurock 的推出做出了贡献，直到该公司于2021年11月被赛诺菲以19亿美元的价格收购。Taitel女士还领导了Kadmon Board的执行商务委员会。从1997年开始，Taitel女士在强生公司担任了多个商业领导职位，在多个治疗领域，包括肿瘤学、免疫学、神经学和妇女医疗保健领域，职位越来越高。Taitel女士拥有天普大学的理学硕士学位、药理学硕士学位（药学等效性）和以色列耶路撒冷希伯来大学药学院的理学学士学位、药学学士学位和生物学学士学位。
- Haya Taitel,has over 30 years of global C-level biopharma commercial and strategic executive experience. Ms. Taitel currently serves as the Head of Sanofi's Global Transplant Franchise where she is responsible for increasing franchise growth and profitability. Prior to her role at Sanofi, Ms. Taitel served as the Chief Commercial Officer of Kadmon Pharmaceuticals, LLC, where she contributed to the launch of Rezurock, from 2013 until the company was acquired by Sanofi for $1.9 billion in November 2021. Ms. Taitel also led Kadmon Board's Executive Commercial Committee. Beginning in 1997, Ms. Taitel had held various commercial leadership positions of increasing seniority at Johnson and Johnson in multiple therapeutic areas, including oncology, immunology, neurology and women's healthcare. Ms. Taitel holds a Master of Science, Pharmacology, (PharmD equivalence) from Temple University and a Bachelor of Science, Pharmacy and Biology from the Hebrew University School of Pharmacy in Jerusalem, Israel.
- Roger J. Garceau
-
Roger J. Garceau在2008年12月加入NPS，同时带来了他在制药产业超过20年的广阔经验。从2002年到2008年12月，Garceau 博士在Sanofi-Aventis担任一些高级领导职务，其最近担任的职务是新产品集团的董事会副总裁。此前，Garceau 博士担任各种职务，包括临床运营部门的副总裁、北美医药和监管事务的临时主管以及美国医药研究的主管，在担任主管期间他领导了一个超过50名专业人员组成的团队，同时监管超过50个受到赞助的临床试验，这些实验分布在在5个不同治疗领域。在Sanofi-Aventis任职前，Garceau博士在Pharmacia Corporation的全球开发和医疗事务部门任职16年，任职期间他成功地为一些市场营销应用做出了贡献。Garceau博士从康涅狄格州费尔菲尔德市Fairfield University获得生物学学士学位，从马塞诸塞大学医学院（University of Massachusetts Medical School）获得医学博士学位，他还是American Academy of Pediatrics的成员。
Roger J. Garceau,has served as a member of Entera Bio Ltd. Board since March 2016, and he served as Entera Bio Ltd. interim CEO From August 2020 to January 4, 2021. Dr. Garceau served also served as Entera Bio Ltd. Chief Development Advisor from December 2016 to December 2021 (excluding the period he served as Entera Bio Ltd. interim CEO). Dr. Garceau has more than 30 years of broad pharmaceutical industry experience. He has been a director of Enterome SA since December 2016, and a director of ArTara Therapeutics since January 2019. Prior to joining Entera, Dr. Garceau served as Chief Medical Officer and Executive Vice President of NPS Pharmaceuticals, Inc. from December 2008 and January 2013 respectively, until February 2015, when NPS Pharmaceuticals, Inc., then traded on Nasdaq, was acquired by Shire plc. (NASDAQ: SHPG). Previously, Dr. Garceau served in several managerial positions with Sanofi-Aventis (NYSE: SNY) from 2002 until 2008, and Pharmacia Corporation from 1986 until 2002. Dr. Garceau is a board-certified pediatrician and is a Fellow of the American Academy of Pediatrics. Dr. Garceau holds a B.S. in Biology from Fairfield University in Fairfield, Connecticut and an M.D. from the University of Massachusetts Medical School. - Roger J. Garceau在2008年12月加入NPS，同时带来了他在制药产业超过20年的广阔经验。从2002年到2008年12月，Garceau 博士在Sanofi-Aventis担任一些高级领导职务，其最近担任的职务是新产品集团的董事会副总裁。此前，Garceau 博士担任各种职务，包括临床运营部门的副总裁、北美医药和监管事务的临时主管以及美国医药研究的主管，在担任主管期间他领导了一个超过50名专业人员组成的团队，同时监管超过50个受到赞助的临床试验，这些实验分布在在5个不同治疗领域。在Sanofi-Aventis任职前，Garceau博士在Pharmacia Corporation的全球开发和医疗事务部门任职16年，任职期间他成功地为一些市场营销应用做出了贡献。Garceau博士从康涅狄格州费尔菲尔德市Fairfield University获得生物学学士学位，从马塞诸塞大学医学院（University of Massachusetts Medical School）获得医学博士学位，他还是American Academy of Pediatrics的成员。
- Roger J. Garceau,has served as a member of Entera Bio Ltd. Board since March 2016, and he served as Entera Bio Ltd. interim CEO From August 2020 to January 4, 2021. Dr. Garceau served also served as Entera Bio Ltd. Chief Development Advisor from December 2016 to December 2021 (excluding the period he served as Entera Bio Ltd. interim CEO). Dr. Garceau has more than 30 years of broad pharmaceutical industry experience. He has been a director of Enterome SA since December 2016, and a director of ArTara Therapeutics since January 2019. Prior to joining Entera, Dr. Garceau served as Chief Medical Officer and Executive Vice President of NPS Pharmaceuticals, Inc. from December 2008 and January 2013 respectively, until February 2015, when NPS Pharmaceuticals, Inc., then traded on Nasdaq, was acquired by Shire plc. (NASDAQ: SHPG). Previously, Dr. Garceau served in several managerial positions with Sanofi-Aventis (NYSE: SNY) from 2002 until 2008, and Pharmacia Corporation from 1986 until 2002. Dr. Garceau is a board-certified pediatrician and is a Fellow of the American Academy of Pediatrics. Dr. Garceau holds a B.S. in Biology from Fairfield University in Fairfield, Connecticut and an M.D. from the University of Massachusetts Medical School.
- Gerald M. Ostrov
-
Gerald M. Ostrov，2011年11月成为本公司董事。2008-2010，他担任Bausch & Lomb 的董事长、首席执行官。此前，他职业生涯的大部分是在Johnson & Johnson度过，曾担任了将近8年的公司集团董事长，负责全球视力护理业务。职业生涯早期，他Johnson & Johnson和Ciba-Geigy担任过行政职务，负责消费者个人护理产品和药品。他获得了Cornell University的工业工程与运营研究学士学位、Harvard University的工商管理硕士学位，现任Oramed Pharmaceuticals的董事。
Gerald M. Ostrov,has served as a member of Entera Bio Ltd. Board since January 2019. Mr. Ostrov consults and invests in new technologies in the medical device and consumer products fields. Mr. Ostrov currently serves on the board of directors of several privately held companies, including Mother's Choice, a natural products company working with industry giants, Addon Optics, an innovative technology company, and Nuvo Group Ltd., a developer of next generation baby and mother health monitoring for both hospital and home Entera Bio Ltd. e. From 2008 to 2010, he served as Chairman and CEO of Bausch & Lomb. There Mr. Ostrov led the stabilization, streamlining and pipeline building of Bausch & Lomb following its going-private transaction. From 1998 until 2006, Mr. Ostrov very successfully served as Company Group Chairman for Johnson & Johnson's Worldwide Vision Care businesses. From 1991 to 1998, Mr. Ostrov worked for Johnson & Johnson and quickly rose to serve as Company Group Chairman of the Consumer and Personal Care businesses in North America. From 1982 to 1991, he served as President of CIBA Consumer Pharmaceuticals Company. From 1976 to 1982, he worked for the Health Care Division of Johnson & Johnson. From 1973 to 1976, Mr. Ostrov worked at Procter & Gamble. Mr. Ostrov holds a B.S. from Cornell and an M.B.A. from Harvard. - Gerald M. Ostrov，2011年11月成为本公司董事。2008-2010，他担任Bausch & Lomb 的董事长、首席执行官。此前，他职业生涯的大部分是在Johnson & Johnson度过，曾担任了将近8年的公司集团董事长，负责全球视力护理业务。职业生涯早期，他Johnson & Johnson和Ciba-Geigy担任过行政职务，负责消费者个人护理产品和药品。他获得了Cornell University的工业工程与运营研究学士学位、Harvard University的工商管理硕士学位，现任Oramed Pharmaceuticals的董事。
- Gerald M. Ostrov,has served as a member of Entera Bio Ltd. Board since January 2019. Mr. Ostrov consults and invests in new technologies in the medical device and consumer products fields. Mr. Ostrov currently serves on the board of directors of several privately held companies, including Mother's Choice, a natural products company working with industry giants, Addon Optics, an innovative technology company, and Nuvo Group Ltd., a developer of next generation baby and mother health monitoring for both hospital and home Entera Bio Ltd. e. From 2008 to 2010, he served as Chairman and CEO of Bausch & Lomb. There Mr. Ostrov led the stabilization, streamlining and pipeline building of Bausch & Lomb following its going-private transaction. From 1998 until 2006, Mr. Ostrov very successfully served as Company Group Chairman for Johnson & Johnson's Worldwide Vision Care businesses. From 1991 to 1998, Mr. Ostrov worked for Johnson & Johnson and quickly rose to serve as Company Group Chairman of the Consumer and Personal Care businesses in North America. From 1982 to 1991, he served as President of CIBA Consumer Pharmaceuticals Company. From 1976 to 1982, he worked for the Health Care Division of Johnson & Johnson. From 1973 to 1976, Mr. Ostrov worked at Procter & Gamble. Mr. Ostrov holds a B.S. from Cornell and an M.B.A. from Harvard.
高管简历
中英对照 | 中文 | 英文- Hillel Galitzer
Hillel Galitzer自2014年2月以来一直担任我们的首席运营官，在此之前，从2012年7月开始担任我们的科学发展总监。Galitzer博士在医学研究和分子生物学方面有着十多年的经验。Galitzer从2010年8月到2014年2月担任Hadasit Bio Holdings Ltd.（特拉维夫证券交易所TASE:HDST and OTC Markets上市公司）分析师和首席运营官。他拥有超过10年的医学研究和分子生物学经验。他是Optivarial Inc.的联合创始人和前首席运营官。他在同行评审的期刊上撰写了许多出版物，并在国际会议和大学演讲和演讲。Galitzer博士在耶路撒冷希伯来大学医学院（Hebrew University Medical School）获得博士学位，在那里他接受了两位甲状旁腺激素和钙调节领域的世界知名研究人员的指导，他在以色列巴伊兰大学（Bar Ilan University）获得工商管理硕士学位，并获得医学学士学位。来自耶路撒冷的希伯来大学医学院。
Hillel Galitzer,has served as Entera Bio Ltd. Chief Operating Officer since February 2014, prior to which he served as Entera Bio Ltd. Director of Scientific Development from July 2012. Dr. Galitzer has more than ten years of experience in medical research and molecular biology. Between August 2010 and February 2014, Dr. Galitzer was an analyst and the chief operating officer for Hadasit Bio Holdings Ltd., a publicly traded company on the Tel Aviv Stock Exchange (TASE: HDST) and OTC markets. He is the co-founder and former chief operating officer of Optivasive Inc. He has written numerous publications in peer-reviewed journals and has lectured and presented in international conferences and universities. Dr. Galitzer received his Ph.D. from the Hebrew University Medical School in Jerusalem, where he was mentored by two world renowned researchers in the areas of parathyroid hormone and calcium regulation, his M.B.A. from Bar Ilan University in Israel and his B.Med.Sc. from the Hebrew University Medical School in Jerusalem.- Hillel Galitzer自2014年2月以来一直担任我们的首席运营官，在此之前，从2012年7月开始担任我们的科学发展总监。Galitzer博士在医学研究和分子生物学方面有着十多年的经验。Galitzer从2010年8月到2014年2月担任Hadasit Bio Holdings Ltd.（特拉维夫证券交易所TASE:HDST and OTC Markets上市公司）分析师和首席运营官。他拥有超过10年的医学研究和分子生物学经验。他是Optivarial Inc.的联合创始人和前首席运营官。他在同行评审的期刊上撰写了许多出版物，并在国际会议和大学演讲和演讲。Galitzer博士在耶路撒冷希伯来大学医学院（Hebrew University Medical School）获得博士学位，在那里他接受了两位甲状旁腺激素和钙调节领域的世界知名研究人员的指导，他在以色列巴伊兰大学（Bar Ilan University）获得工商管理硕士学位，并获得医学学士学位。来自耶路撒冷的希伯来大学医学院。
- Hillel Galitzer,has served as Entera Bio Ltd. Chief Operating Officer since February 2014, prior to which he served as Entera Bio Ltd. Director of Scientific Development from July 2012. Dr. Galitzer has more than ten years of experience in medical research and molecular biology. Between August 2010 and February 2014, Dr. Galitzer was an analyst and the chief operating officer for Hadasit Bio Holdings Ltd., a publicly traded company on the Tel Aviv Stock Exchange (TASE: HDST) and OTC markets. He is the co-founder and former chief operating officer of Optivasive Inc. He has written numerous publications in peer-reviewed journals and has lectured and presented in international conferences and universities. Dr. Galitzer received his Ph.D. from the Hebrew University Medical School in Jerusalem, where he was mentored by two world renowned researchers in the areas of parathyroid hormone and calcium regulation, his M.B.A. from Bar Ilan University in Israel and his B.Med.Sc. from the Hebrew University Medical School in Jerusalem.
- Dana Yaacov Garbeli
自2019年6月以来，Dana Yaacov Garbeli一直担任我们驻以色列的首席财务官。Yaacov-Garbeli女士目前是A2Z Finance Ltd的合伙人，在那里她担任私人和上市公司的外包首席财务官，并提供额外的咨询和会计服务。Yaacov-Garbeli女士此前曾在普华永道以色列公司（PricewaterhouseCoopers Israel）任职，包括短期借调到普华永道纽约公司（PricewaterhouseCoopers New York）担任高级经理，负责审计总部位于以色列，美国和欧洲的公共和私人持有的跨国公司，主要是制药和生物技术部门。Yaacov-Garbeli女士拥有管理与学术研究学院（College of Management and Academic Studies）的会计与商业管理学士学位和财务管理工商管理硕士学位。Yaacov-Garbeli女士是以色列的一名注册会计师。
Dana Yaacov Garbeli,has served as Entera Bio Ltd. Chief Financial Officer since July 2022. Prior that, Ms. Yaacov-Garbeli served as Entera Bio Ltd. Israel-based Chief Financial Officer from June 2019 through July 2022. Ms. Yaacov-Garbeli has over 15 years of chief finance and accounting experience. She previously served as Senior Manager at PwC Israel overseeing audits of public and private companies. She has significant experience in financial planning, operations management, external and internal audit for public multinational companies under US GAAP, IFRS and PCAOB standards. Ms. Yaacov-Garbeli is also a partner at A2Z-Finance, a company that provides financial and accounting services. Ms. Yaacov-Garbeli holds a B.A in accounting and business management and an MBA in financial management from The College of Management and Academic studies. Ms. Yaacov-Garbeli is a Certified Public Accountant in Israel.- 自2019年6月以来，Dana Yaacov Garbeli一直担任我们驻以色列的首席财务官。Yaacov-Garbeli女士目前是A2Z Finance Ltd的合伙人，在那里她担任私人和上市公司的外包首席财务官，并提供额外的咨询和会计服务。Yaacov-Garbeli女士此前曾在普华永道以色列公司（PricewaterhouseCoopers Israel）任职，包括短期借调到普华永道纽约公司（PricewaterhouseCoopers New York）担任高级经理，负责审计总部位于以色列，美国和欧洲的公共和私人持有的跨国公司，主要是制药和生物技术部门。Yaacov-Garbeli女士拥有管理与学术研究学院（College of Management and Academic Studies）的会计与商业管理学士学位和财务管理工商管理硕士学位。Yaacov-Garbeli女士是以色列的一名注册会计师。
- Dana Yaacov Garbeli,has served as Entera Bio Ltd. Chief Financial Officer since July 2022. Prior that, Ms. Yaacov-Garbeli served as Entera Bio Ltd. Israel-based Chief Financial Officer from June 2019 through July 2022. Ms. Yaacov-Garbeli has over 15 years of chief finance and accounting experience. She previously served as Senior Manager at PwC Israel overseeing audits of public and private companies. She has significant experience in financial planning, operations management, external and internal audit for public multinational companies under US GAAP, IFRS and PCAOB standards. Ms. Yaacov-Garbeli is also a partner at A2Z-Finance, a company that provides financial and accounting services. Ms. Yaacov-Garbeli holds a B.A in accounting and business management and an MBA in financial management from The College of Management and Academic studies. Ms. Yaacov-Garbeli is a Certified Public Accountant in Israel.
- Arthur Santora
Arthur Santora自2018年9月起担任首席医疗官。Santora博士在生物制药行业拥有超过30年的经验。1989年6月至2017年3月，他的大部分职业生涯都在默克制药公司的临床研究团队中度过，在那里他是首席临床研究医师，负责世界上处方最多的骨质疏松症治疗药物之一Fosamax&174；Alendronate钠的大部分临床开发。他曾密切参与Merck’；s每周一次的Fosamax加D阿仑膦酸钠/维生素D3复合片的临床开发，这是美国第一个药物/维生素复合片。在2017年服务终止之前，他在默克的职位是临床研究科学助理Vice President，在那里他直接负责Fosamax/Fosamax Plus D的所有临床研究的技术和科学支持，并为许多其他骨质疏松症和内分泌营销和研究药物的开发做出了贡献。加入Merck公司之前，他曾担任美国FDA的医疗官，随后担任底特律Wayne State University Medical School的教员。Santora博士是新泽西州新不伦瑞克Rutgers Robert Wood Johnson医学院临床学院的临床副教授。他在埃默里大学（Emory）接受内科研究生培训，在贝塞斯达国立卫生研究院（the NIH in Bethesda）接受内分泌学和代谢子专业培训。Santora博士在亚特兰大埃默里大学（Emory University）获得生物化学硕士学位和博士学位。
Arthur Santora,has served as Entera Bio Ltd. Chief Medical Officer since September 2018. Dr. Santora has more than 30 years of experience in the biopharmaceutical industry. He spent the majority of his career in the clinical research team at Merck & Co., Inc., from June 1989 to March 2017, where he was the lead clinical research physician responsible for much of the clinical development of Fosamax (alendronate sodium), one of the world's most prescribed osteoporosis treatments. He was closely involved in the clinical development of Merck's once-weekly Fosamax Plus D (alendronate sodium/ vitamin D3 combination tablets), the first drug/vitamin combination tablet in the US. His position at Merck immediately prior to his termination of services in 2017 was Scientific Associate Vice President of Clinical Research, where he was directly responsible for the technical and scientific support for all clinical research of Fosamax/Fosamax plus D and contributed to the development of many other osteoporosis and endocrine marketed and investigational drugs. Prior to joining Merck, he served as a Medical Officer at the US FDA and subsequently was a faculty member at Wayne State University Medical School in Detroit. Dr. Santora is a Clinical Associate Professor at the clinical faculty of Rutgers Robert Wood Johnson Medical School in New Brunswick, New Jersey. He has graduate training in Internal Medicine at Emory, and its Endocrinology and Metabolism subspecialty at the NIH in Bethesda. Dr. Santora received his M.D. and Ph.D. in biochemistry from Emory University in Atlanta.- Arthur Santora自2018年9月起担任首席医疗官。Santora博士在生物制药行业拥有超过30年的经验。1989年6月至2017年3月，他的大部分职业生涯都在默克制药公司的临床研究团队中度过，在那里他是首席临床研究医师，负责世界上处方最多的骨质疏松症治疗药物之一Fosamax&174；Alendronate钠的大部分临床开发。他曾密切参与Merck’；s每周一次的Fosamax加D阿仑膦酸钠/维生素D3复合片的临床开发，这是美国第一个药物/维生素复合片。在2017年服务终止之前，他在默克的职位是临床研究科学助理Vice President，在那里他直接负责Fosamax/Fosamax Plus D的所有临床研究的技术和科学支持，并为许多其他骨质疏松症和内分泌营销和研究药物的开发做出了贡献。加入Merck公司之前，他曾担任美国FDA的医疗官，随后担任底特律Wayne State University Medical School的教员。Santora博士是新泽西州新不伦瑞克Rutgers Robert Wood Johnson医学院临床学院的临床副教授。他在埃默里大学（Emory）接受内科研究生培训，在贝塞斯达国立卫生研究院（the NIH in Bethesda）接受内分泌学和代谢子专业培训。Santora博士在亚特兰大埃默里大学（Emory University）获得生物化学硕士学位和博士学位。
- Arthur Santora,has served as Entera Bio Ltd. Chief Medical Officer since September 2018. Dr. Santora has more than 30 years of experience in the biopharmaceutical industry. He spent the majority of his career in the clinical research team at Merck & Co., Inc., from June 1989 to March 2017, where he was the lead clinical research physician responsible for much of the clinical development of Fosamax (alendronate sodium), one of the world's most prescribed osteoporosis treatments. He was closely involved in the clinical development of Merck's once-weekly Fosamax Plus D (alendronate sodium/ vitamin D3 combination tablets), the first drug/vitamin combination tablet in the US. His position at Merck immediately prior to his termination of services in 2017 was Scientific Associate Vice President of Clinical Research, where he was directly responsible for the technical and scientific support for all clinical research of Fosamax/Fosamax plus D and contributed to the development of many other osteoporosis and endocrine marketed and investigational drugs. Prior to joining Merck, he served as a Medical Officer at the US FDA and subsequently was a faculty member at Wayne State University Medical School in Detroit. Dr. Santora is a Clinical Associate Professor at the clinical faculty of Rutgers Robert Wood Johnson Medical School in New Brunswick, New Jersey. He has graduate training in Internal Medicine at Emory, and its Endocrinology and Metabolism subspecialty at the NIH in Bethesda. Dr. Santora received his M.D. and Ph.D. in biochemistry from Emory University in Atlanta.
- Miranda J. Toledano
MirandaJ.Toledano自2018年9月以来一直担任我们的董事会成员。Toledano女士担任Trigr Therapeutics（一家临床阶段免疫肿瘤公司，专注于双特异性抗体）的首席运营官/首席财务官。此前，从2016年9月至2017年8月，Toledano女士担任Sorrento Therapeutics NASDAQ:SRNE的执行管理团队执行副总裁。从2012年到2016年，Toledano女士担任MLV&Co.（被B.Riley FBR&Co.收购）的梦百合投资银行业务主管，在那里她完成了总价值超过40亿美元的股票资本市场交易。加入MLV之前，从2004年到2010年，Toledano女士在Royalty Pharma的投资集团任职，该公司是一家领先的投资公司，拥有超过150亿美元的生物治疗特许权使用费资产。从1998年到2003年，Toledano女士领导安永会计师事务所（Ernst&Young）（以色列）的生命科学公司财务集团。Toledano女士拥有塔夫茨大学（Tufts University）经济学学士学位和纽约大学斯特恩商学院（NYU Stern School of Business）金融与创业工商管理硕士学位。
Miranda J. Toledano,has served as the Company's Chief Executive Officer, or CEO, since July 2022. Prior to her appointment as CEO, Ms. Toledano served as the Company's Chief Business Officer, Chief Financial Officer and Head of Corporate Strategy since May 2022. Ms. Toledano has over 20 years of C-level leadership, principal investment and Wall Street/capital market experience in the biotech sector. Ms. Toledano has served as a member of Entera Bio Ltd. Board of Directors (the "Board") since 2018, and as Member of the Scientific Advisory Committee since February 2022. Previously, Miranda served as Chief Operating Officer, Chief Financial Officer, and Director of TRIGR Therapeutics, an oncology focused, clinical stage bispecific antibody company, from August 2018 until its acquisiion by Compass Therapeutics (Nasdaq: CMPX) in June 2021. At TRIGR, Miranda oversaw the clinical development of lead asset TR009 (now CTX-009) and led strategic execution, including a $117 million China License Transaction and acquisition by CMPX. Previously, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings (IPOs, ATMs, and follow-ons) totaling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma (Nasdaq: RPRX) from 2004 to 2010. Ms. Toledano is also a member of the board of directors of Journey Medical (Nasdaq: DERM) and NEXGEL (Nasdaq: NXGL). Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.- MirandaJ.Toledano自2018年9月以来一直担任我们的董事会成员。Toledano女士担任Trigr Therapeutics（一家临床阶段免疫肿瘤公司，专注于双特异性抗体）的首席运营官/首席财务官。此前，从2016年9月至2017年8月，Toledano女士担任Sorrento Therapeutics NASDAQ:SRNE的执行管理团队执行副总裁。从2012年到2016年，Toledano女士担任MLV&Co.（被B.Riley FBR&Co.收购）的梦百合投资银行业务主管，在那里她完成了总价值超过40亿美元的股票资本市场交易。加入MLV之前，从2004年到2010年，Toledano女士在Royalty Pharma的投资集团任职，该公司是一家领先的投资公司，拥有超过150亿美元的生物治疗特许权使用费资产。从1998年到2003年，Toledano女士领导安永会计师事务所（Ernst&Young）（以色列）的生命科学公司财务集团。Toledano女士拥有塔夫茨大学（Tufts University）经济学学士学位和纽约大学斯特恩商学院（NYU Stern School of Business）金融与创业工商管理硕士学位。
- Miranda J. Toledano,has served as the Company's Chief Executive Officer, or CEO, since July 2022. Prior to her appointment as CEO, Ms. Toledano served as the Company's Chief Business Officer, Chief Financial Officer and Head of Corporate Strategy since May 2022. Ms. Toledano has over 20 years of C-level leadership, principal investment and Wall Street/capital market experience in the biotech sector. Ms. Toledano has served as a member of Entera Bio Ltd. Board of Directors (the "Board") since 2018, and as Member of the Scientific Advisory Committee since February 2022. Previously, Miranda served as Chief Operating Officer, Chief Financial Officer, and Director of TRIGR Therapeutics, an oncology focused, clinical stage bispecific antibody company, from August 2018 until its acquisiion by Compass Therapeutics (Nasdaq: CMPX) in June 2021. At TRIGR, Miranda oversaw the clinical development of lead asset TR009 (now CTX-009) and led strategic execution, including a $117 million China License Transaction and acquisition by CMPX. Previously, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings (IPOs, ATMs, and follow-ons) totaling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma (Nasdaq: RPRX) from 2004 to 2010. Ms. Toledano is also a member of the board of directors of Journey Medical (Nasdaq: DERM) and NEXGEL (Nasdaq: NXGL). Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.